单克隆抗体作为抗感染产品:前景可期?
本叙述性综述通过检索Medline数据库、已上市抗感染单克隆抗体的官方文件及ClinicalTrials.gov上的在研试验,评估了单克隆抗体干预感染性疾病的潜力,指出其可用于生物威胁及新发再发传染病的防护,但开发成本高昂阻碍大规模应用,未来需探索替代给药方式并尽早与监管机构沟通。
要点
- 已获批的抗感染单克隆抗体数量稀少,与其他疾病领域形成鲜明对比。
- 单克隆抗体有望作为应对生物威胁及新发再发传染病的 readily available 防护工具。
- 开发成本高昂是单克隆抗体大规模推广的主要障碍,需探索替代给药方式。
核心结论
- 单克隆抗体可能成为治疗或预防感染的重要工具,前提是感染发生率足够高以证明需求合理,且现有替代方案被认为不完全充分。
- 未来举措需解决开发过程中的高昂成本问题。
- 更大规模实施替代给药方式的可行性值得进一步探索。
- 为确保监管成功的最佳前景,鼓励与主管机构尽早对话。
研究设计与样本
- 叙述性综述,检索Medline数据库,并补充已上市抗感染单克隆抗体的官方文件,同时通过ClinicalTrials.gov识别在研试验。
主要发现
- 识别出少数已将单克隆抗体纳入治疗手段的感染,并强调其作为 readily available 防护工具应对生物威胁及新发再发传染病的潜力。
- 综述了单克隆抗体的历史背景和主要特征,认为其具有更广泛的适用性,并列举了正在进行的治疗开发相关示例。
- 概述了阻碍单克隆抗体大规模成功引入的因素,并就如何可能解决部分局限性提出了思考。
临床怎么用
- 单克隆抗体可能成为治疗或预防感染的重要工具,适用于感染发生率足够高以证明需求合理且现有替代方案被认为不完全充分的情况。
- 未来举措需解决开发过程中的高昂成本问题。
- 更大规模实施替代给药方式的可行性值得进一步探索。
- 为确保监管成功的最佳前景,鼓励与主管机构尽早对话。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The paucity of licensed monoclonal antibodies (mAbs) in the infectious diseases arena strongly contrasts with the ready availability of these therapeutics for use in other conditions. AIMS: This narrative review aims to assess the potential of monoclonal antibody-based interventions for infectious diseases. SOURCES: A review of the literature via the Medline database was performed and complemented by published official documents on licensed anti-infective mAbs. In addition, ongoing trials were identified through a search of the clinical trial registration platform ClinicalTrials.gov. CONTENT: We identified the few infections for which mAbs have been added to the therapeutic armamentarium and stressed their potential in representing a readily available protection tool against biothreats and newly emerging and reemerging infectious agents. In reviewing the historical context and main features of mAbs, we assert a potentially wider applicability and cite relevant examples of ongoing therapeutic developments. Factors hindering successful introduction of mAbs on a larger scale are outlined and thoughts are offered on how to possibly address some of these limitations. IMPLICATIONS: mAbs may represent important tools in treating or preventing infections occurring with reasonably sufficient prevalence to justify demand and for which existing alternatives are not deemed fully adequate. Future initiatives need to address the prohibitive costs encountered in the development process. The feasibility of more large-scale administration of alternative modalities merits further exploration. In order to ensure optimal prospect of regulatory success, an early dialogue with competent authorities is encouraged.
引用
- Pelfrene E, Mura M, Cavaleiro Sanches A, et al. Monoclonal antibodies as anti-infective products: a promising future? Clin Microbiol Infect. 2018. PMID: 29715552. doi:10.1016/j.cmi.2018.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。